Photo: Tevapharm.com

3 March 2014Asia

Indian court dismisses Teva’s bid to block Copaxone generic

The Delhi High Court has dismissed Teva’s action to stop Hyderabad-based Natco Pharma from marketing a generic version of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

'This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards

‘I’m breaking new ground’: Mölnlycke’s first TM attorney charts a new course

Drug approvals up but global innovation declines

‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel